![]() ![]() While Kite is prepared for a commercial launch in the United States as manufacturing preparation are complete, the company is currently building infrastructure in Europe. The candidate is also under review in the EU with a tentative approval expected in 2018. ![]() This CAR T therapy is currently under priority review in the United States and the FDA is expected to give a decision on Nov 29, 2017. The Biologics License Application (BLA) for the candidate was submitted in Mar 2017. The most advanced therapy candidate in Kite’s pipeline is axicabtagene ciloleucel (axi-cel) which is being developed for the treatment of refractory aggressive non-Hodgkin lymphoma, which includes diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL). We note that Kite is a pioneer in cell therapy having developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on the type of cancer. The acquisition is expected to be neutral to the bottom line by the third year and accretive thereafter. The transaction was approved by shareholders of both companies and is expected to close by the fourth quarter of 2017. ![]() The price represents a 28% premium over the closing share price of Kite as of Aug 25, 2017. KITE to foray into the emerging field of cell therapy.Īs per the agreement, Gilead will pay $180.00 per share in cash at a transaction valued at approximately $11.9 billion. GILD announced that it will buy Kite Pharma, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |